Neuroblastoma in Older Children May Respond to Tazemetostat
Emily Bernstein, PhD of @IcahnMountSinai explains neuroblastoma in older children & adolescents harboring deletions within a gene called ATRX may be responsive to tazemetostat.
Related Articles
BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Lead to Longevity Leaps?
Learn about the benefits of risk-reducing surgeries in young BRCA mutation carriers with a history of breast cancer.
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results
Get insights into the PATINA Phase 3 trial studying Palbociclib in ER+/HER2+ Metastatic Breast Cancer, and how it aims to improve outcomes in these patients.
Breast Cancer New Nemeses: CDK4/6 Inhibitors Rave Against Recurrence, But Have They Crashed the EBC Party in NATALEE & monarchE’s Real-World Dance-Off?
Explore how CDK4/6 inhibitors are revolutionizing early breast cancer treatment. Find out about the expanded treatment scope and long-term efficacy.
ctDNA: ZEST Trial Cleans Up Breast Cancer Treatment – Niraparib (ZEJULA) vs. Placebo in High-Risk TNBC and BRCA-Mutated Patients
Findings from the ZEST trial highlight the potential of ctDNA surveillance in breast cancer management. Discover the role of Niraparib in enhancing disease-free survival.
ENHERTU® (Trastuzumab Deruxtecan, T-DXd) Outperforms Chemotherapy in Metastatic Breast Cancer: SABCS 2024 DESTINY-Breast06 Results
New data from DESTINY-Breast06 study presented at SABCS 2024. Explore efficacy of ENHERTU in hormone receptor-positive metastatic breast cancer patients.
EMBER-3 Reveal: Imlunestrant – Standalone Star or Team Player with Abemaciclib?
Get critical insights into advanced breast cancer treatment from the Phase 3 EMBER-3 trial. Explore the efficacy of Imlunestrant and its potential in improving patient…
FDA Approves Lazcluze Rybrevant Combo in Advanced NSCLC: Data Revealed
FDA approves combination treatment for advanced non-small cell lung cancer (NSCLC) targeting specific EGFR mutations. Learn about the MARIPOSA trial results,…
FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
FDA approved pembrolizumab (Keytruda) combined with chemotherapy for mesothelioma treatment. A new option for patients battling this aggressive disease.
SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
FDA approves Kisqali for early high-risk breast cancer treatment. Learn about this new treatment option and its benefits for patients.
FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer ESMO 2024
Download Slides: https://oncologytube.com/slides-fda-approves-kisqali-ribociclib-for-early-high-risk-breast-cancer/The FDA has approved Kisqali (ribociclib) …